| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
37,945 |
36,171 |
$8.65M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,613 |
4,481 |
$1.11M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,540 |
2,454 |
$587K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,160 |
1,123 |
$282K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
432 |
416 |
$88K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
577 |
536 |
$17K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,996 |
2,522 |
$11K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
46 |
46 |
$5K |
| 99000 |
|
5,727 |
5,301 |
$2K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,181 |
1,161 |
$625.90 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,701 |
4,594 |
$0.00 |
| 81002 |
|
3,550 |
3,405 |
$0.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,861 |
6,724 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
13 |
12 |
$0.00 |
| 81025 |
|
170 |
167 |
$0.00 |
| 69209 |
|
20 |
12 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
71 |
70 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
769 |
751 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
366 |
356 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
241 |
239 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
375 |
361 |
$0.00 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
148 |
140 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
675 |
635 |
$0.00 |
| 87807 |
|
263 |
259 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
30 |
25 |
$0.00 |
| G8433 |
Screening for depression not completed, documented patient or medical reason |
85 |
84 |
$0.00 |
| 90686 |
|
18 |
18 |
$0.00 |